Medicare Part B And Accelerated Approvals: MedPAC Mulls Use Of CED Versus Payment Caps
Executive Summary
Medicare advisory panel discusses ongoing issues around launch prices that were not addressed by the government price controls targeting older drugs enacted as part of the Inflation Reduction Act.
You may also be interested in...
Accelerated Approval Price Trends Show Sponsors Can ‘Lose But Not Win’ From Confirmatory Trials
Study drills down into the lack of economic incentives for conducting confirmatory studies to inform policies that could remedy to the situation.
MedPAC’s Message To Congress: Drug Pricing Still Needs Attention
The US Medicare Payment Advisory Commission is continuing its work on proposals to overhaul federal payment for physician administered drugs. That is an ominous message for the biopharma industry as it reels from passage of dramatic pricing legislation earlier this year.
Medicare Price ‘Negotiation’ Process Gets Broad Brush Treatment In New Law
With enactment of the drug pricing reform provisions in the Inflation Reduction Act, stakeholders now turn their attention to the implementing regulations that will be developed by the Centers for Medicare and Medicaid Services.